Invention Grant
- Patent Title: Ratios of sFlt-1 to P1GF or endoglin to P1GF as biomarkers for preeclampsia related adverse outcomes after birth
-
Application No.: US16998444Application Date: 2020-08-20
-
Publication No.: US12105096B2Publication Date: 2024-10-01
- Inventor: Martin Hund , Thomas Dieterle , Olav Lapaire
- Applicant: Roche Diagnostics Operations, Inc.
- Applicant Address: US IN Indianapolis
- Assignee: Roche Diagnostics Operations, Inc.
- Current Assignee: Roche Diagnostics Operations, Inc.
- Current Assignee Address: US IN Indianapolis
- Agency: Taft Stettinius & Hollister LLP
- Priority: EP 152447 2014.01.24
- Main IPC: G01N33/68
- IPC: G01N33/68
Abstract:
The present invention is directed to a method for predicting the risk of a female subject to develop postpartum HELLP syndrome, postpartum preeclampsia, or postpartum eclampsia. The method is based on the determination of the levels of i) sFlt-1 and PlGF, or ii) Endoglin and PlGF in a first sample obtained from said subject before delivery of baby, and a second sample of from said subject obtained after delivery of baby. Moreover, encompassed by the invention are devices and kits for carrying out the method of the present invention.
Public/Granted literature
- US20200378981A1 PREDICTION OF POSTPARTUM HELLP SYNDROME, POSTPARTUM ECLAMPSIA OR POSTPARTUM PREECLAMPSIA Public/Granted day:2020-12-03
Information query
IPC分类:
